These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 27249713)

  • 1. Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment.
    Berghoff AS; Venur VA; Preusser M; Ahluwalia MS
    Am Soc Clin Oncol Educ Book; 2016; 35():e116-22. PubMed ID: 27249713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
    Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors.
    Barlesi F; Tomasini P
    Lancet Oncol; 2020 May; 21(5):607-608. PubMed ID: 32251624
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B; Campo MJ; Gainor JF
    Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases.
    Li W; Yu H
    J Cancer Res Clin Oncol; 2020 Jan; 146(1):137-152. PubMed ID: 31813004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
    Zhou S; Xie J; Huang Z; Deng L; Wu L; Yu J; Meng X
    Cancer Lett; 2021 Apr; 502():166-179. PubMed ID: 33450361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of immune checkpoint blockade for brain metastases.
    Harary M; Reardon DA; Iorgulescu JB
    CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
    [No Abstract]   [Full Text] [Related]  

  • 8. High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment.
    Sánchez-Magraner L; Miles J; Baker CL; Applebee CJ; Lee DJ; Elsheikh S; Lashin S; Withers K; Watts AG; Parry R; Edmead C; Lopez JI; Mehta R; Italiano A; Ward SG; Parker PJ; Larijani B
    Cancer Res; 2020 Oct; 80(19):4244-4257. PubMed ID: 32855204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
    Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
    Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases.
    Nunno VD; Nuvola G; Mosca M; Maggio I; Gatto L; Tosoni A; Lodi R; Franceschi E; Brandes AA
    Immunotherapy; 2021 Apr; 13(5):419-432. PubMed ID: 33472433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
    Hermel DJ; Ott PA
    Cancer Metastasis Rev; 2017 Mar; 36(1):43-50. PubMed ID: 28181070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint inhibitor immunotherapy in kidney cancer.
    Xu W; Atkins MB; McDermott DF
    Nat Rev Urol; 2020 Mar; 17(3):137-150. PubMed ID: 32020040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
    Frydenlund N; Mahalingam M
    Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Immunotherapy and Lung Cancer.
    Sánchez de Cos Escuín J
    Arch Bronconeumol; 2017 Dec; 53(12):682-687. PubMed ID: 28823733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin.
    Kattan J; Rassy EE; Assi T; Bakouny Z; Pavlidis N
    Crit Rev Oncol Hematol; 2018 Oct; 130():60-69. PubMed ID: 30196913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitors for Brain Metastases.
    Tan AC; Heimberger AB; Menzies AM; Pavlakis N; Khasraw M
    Curr Oncol Rep; 2017 Jun; 19(6):38. PubMed ID: 28417311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Qian JM; Yu JB; Kluger HM; Chiang VL
    Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer.
    Remon J; Besse B
    Curr Opin Oncol; 2017 Mar; 29(2):97-104. PubMed ID: 28059852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.
    Flynn MJ; Larkin JMG
    Expert Opin Pharmacother; 2017 Oct; 18(14):1477-1490. PubMed ID: 28820000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
    Loo K; Daud AI
    Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.